BET'ing on Dual JAK/BET Inhibition as a Therapeutic Strategy for Myeloproliferative Neoplasms

Qingfei Jiang; Catriona Jamieson

doi:10.1016/j.ccell.2017.12.007

BET'ing on Dual JAK/BET Inhibition as a Therapeutic Strategy for Myeloproliferative Neoplasms

Cancer Cell. 2018 Jan 8;33(1):3-5. doi: 10.1016/j.ccell.2017.12.007.

Authors

Qingfei Jiang¹, Catriona Jamieson²

Affiliations

¹ Division of Regenerative Medicine, Department of Medicine, Moores Cancer Center and Sanford Consortium for Regenerative Medicine, University of California, San Diego, La Jolla, CA, USA.
² Division of Regenerative Medicine, Department of Medicine, Moores Cancer Center and Sanford Consortium for Regenerative Medicine, University of California, San Diego, La Jolla, CA, USA. Electronic address: cjamieson@ucsd.edu.

PMID: 29316431
DOI: 10.1016/j.ccell.2017.12.007

Abstract

In this issue of Cancer Cell, Kleppe et al. describe a combination strategy designed to inhibit BET bromodomain and JAK/STAT signaling as a method for effectively inhibiting NF-κB and cytokine production in myeloproliferative neoplasms (MPNs). The results provide a strong rationale for clinical evaluation of dual BET/JAK inhibition in MPNs.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Humans
Myeloproliferative Disorders*
NF-kappa B
Neoplasms
STAT Transcription Factors*
Signal Transduction

Substances

NF-kappa B
STAT Transcription Factors

Abstract

Publication types

MeSH terms

Substances

Grants and funding